Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Addex Therapeutics Ltd
  6. News
  7. Summary
    ADXN   CH0029850754


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Addex to Present at the 20th Annual Needham Virtual Healthcare Conference

04/13/2021 | 01:00am EDT

Geneva, Switzerland, April 13, 2021 - Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that Tim Dyer, Chief Executive Officer, will present at the 20th Annual Needham Virtual Healthcare Conference (April 12-15, 2021).

In his presentation, which is scheduled for Tuesday, April 13, 2021 at 08:00 EST, Mr Dyer will provide a corporate update and discuss recent developments at Addex. The video presentation will be available for viewing on-demand by registered participants via this link from the time of the presentation and subsequently on the Events page of the Company’s website (www.addextherapeutics.com).

Management will be available for virtual one-on-one meetings throughout the conference. For more information or to schedule a one-on-one meeting with management, please contact your conference representative or James@HaydenIR.com.

About Addex Therapeutics:
Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders. Allosteric modulators offer several potential advantages over conventional non-allosteric molecules and may offer an improved therapeutic approach to conventional "orthosteric" small molecule or biological drugs. Adder’s allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention. adder’s lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is poised to start a pivotal registration clinical trial for Parkinson’s disease levodopa induced dyskinesia (PD-LID) in Q2 2021. Addex is also investigating dipraglurant's therapeutic use in blepharospasm (a type of dystonia), for which a clinical trial is expected to be initiated in Q2 2021. Addex's third clinical program, ADX71149 (mGlu2 positive allosteric modulator or PAM), developed in collaboration with Janssen Pharmaceuticals, Inc, is scheduled to enter a phase 2a proof of concept clinical study for the treatment of epilepsy in Q2 2021. Addex’s GABAB PAM program has been licensed to Indivior PLC who are focused on development for the treatment of addiction. Preclinical programs include GABAB PAM for CMT1A, mGlu7 NAM for PTSD, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative disorders. Addex is listed on the SIX Swiss Exchange and the NASDAQ Capital Market and trades under the ticker symbol "ADXN".

Press Contacts:

Tim Dyer
Chief Executive Officer
+41 22 884 15 55
Mike Sinclair
Partner, Halsin Partners
+44 (0) 20 7318 2955
James Carbonara
Hayden IR

Forward Looking Statements:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including in respect of the anticipated initiation of clinical trials. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release, are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, uncertainties related to market conditions. These and other risks and uncertainties are described in the Company’s Annual Report on Form 20-F filed with the SEC on March 11, 2021, as well as market conditions and regulatory review.
Any forward-looking statements contained in this press release represent Addex Therapeutics’ views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Addex Therapeutics explicitly disclaims any obligation to update any forward-looking statements.

Primary Logo

© GlobeNewswire 2021
06/07ADDEX THERAPEUTICS  : Commences Enrollment in Phase 2 Trial of Epilepsy Drug
06/07ADDEX THERAPEUTICS  : First patients enrolled into multi-center U.S. study (Form..
06/07ADDEX THERAPEUTICS  : Enrolls First Patient in Mid-Stage Study of Epilepsy Drug
06/07PRESS RELEASE : Addex Starts Phase 2 Clinical Study of ADX71149 for Epilepsy
06/07Addex Starts Phase 2 Clinical Study of ADX71149 for Epilepsy
05/24PRESS RELEASE : Addex to Participate at the Benchmark Company Healthcare House C..
05/24ADDEX THERAPEUTICS  : to Participate at the Benchmark Company Healthcare House C..
05/24Addex to Participate at the Benchmark Company Healthcare House Call Conferenc..
05/17PRESS RELEASE : Addex's Dipraglurant Restores Synaptic Plasticity in Models of D..
05/17Addex's Dipraglurant Restores Synaptic Plasticity in Models of Dystonia
More news
Sales 2021 1,61 M 1,79 M 1,79 M
Net income 2021 -15,1 M -16,7 M -16,7 M
Net Debt 2021 5,28 M 5,86 M 5,86 M
P/E ratio 2021 -3,72x
Yield 2021 -
Capitalization 69,7 M 77,6 M 77,5 M
EV / Sales 2021 46,6x
EV / Sales 2022 76,6x
Nbr of Employees 27
Free-Float 77,2%
Duration : Period :
Addex Therapeutics Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ADDEX THERAPEUTICS LTD
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus UNDERPERFORM
Number of Analysts 2
Average target price 1,08 CHF
Last Close Price 1,60 CHF
Spread / Highest target -32,5%
Spread / Average Target -32,5%
Spread / Lowest Target -32,5%
EPS Revisions
Managers and Directors
Timothy Dyer Chief Executive Officer & Director
Lénaic Teyssédou Head-Finance
Vincent M. Lawton Chairman
Roger G. Mills Director & Chief Medical Officer
Raymond George Hill Director
Sector and Competitors
1st jan.Capitalization (M$)
MODERNA, INC.98.54%87 874
LONZA GROUP AG16.32%54 656
CELLTRION, INC.-21.73%32 458
SEAGEN INC.-10.76%28 416